CA2542507C - Treatment of inflammatory bowel disease - Google Patents
Treatment of inflammatory bowel disease Download PDFInfo
- Publication number
- CA2542507C CA2542507C CA2542507A CA2542507A CA2542507C CA 2542507 C CA2542507 C CA 2542507C CA 2542507 A CA2542507 A CA 2542507A CA 2542507 A CA2542507 A CA 2542507A CA 2542507 C CA2542507 C CA 2542507C
- Authority
- CA
- Canada
- Prior art keywords
- colitis
- rats
- alkyl
- use according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002952084A AU2002952084A0 (en) | 2002-10-16 | 2002-10-16 | Treatment of inflammatory bowel disease |
AU2002952084 | 2002-10-16 | ||
AU2003902452 | 2003-05-20 | ||
AU2003902452A AU2003902452A0 (en) | 2003-05-20 | 2003-05-20 | Treatment of inflammatory bowel disease |
PCT/AU2003/001365 WO2004035078A1 (en) | 2002-10-16 | 2003-10-15 | Treatment of inflammatory bowel disease |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2542507A1 CA2542507A1 (en) | 2004-04-29 |
CA2542507C true CA2542507C (en) | 2013-04-16 |
Family
ID=32108554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2542507A Expired - Fee Related CA2542507C (en) | 2002-10-16 | 2003-10-15 | Treatment of inflammatory bowel disease |
Country Status (6)
Country | Link |
---|---|
US (2) | US7410945B2 (ja) |
EP (1) | EP1558277B1 (ja) |
JP (1) | JP4818726B2 (ja) |
AT (1) | ATE509632T1 (ja) |
CA (1) | CA2542507C (ja) |
WO (1) | WO2004035078A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPS160602A0 (en) | 2002-04-08 | 2002-05-16 | University Of Queensland, The | Therapeutic method |
WO2004035078A1 (en) * | 2002-10-16 | 2004-04-29 | The University Of Queensland | Treatment of inflammatory bowel disease |
AU2002952086A0 (en) * | 2002-10-16 | 2002-11-07 | The University Of Queensland | Treatment of osteoarthritis |
US7885748B2 (en) * | 2006-09-13 | 2011-02-08 | Gm Global Technology Operations, Inc. | Virtual accelerometer |
CN101854933A (zh) * | 2007-09-10 | 2010-10-06 | 钙医学公司 | 调节细胞内钙的化合物 |
WO2009052489A2 (en) * | 2007-10-19 | 2009-04-23 | Alba Therapeutics Corporation | Novel inhibitors of mammalian tight junction opening |
EP2116618A1 (en) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
EP2321303B1 (en) * | 2008-08-27 | 2019-11-27 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US8524763B2 (en) * | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
US8618307B2 (en) | 2009-09-16 | 2013-12-31 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
WO2019075319A1 (en) * | 2017-10-12 | 2019-04-18 | Board Of Regents, The University Of Texas System | COMPOSITIONS AND METHODS FOR TREATING PAIN IN WOMEN |
CN116115582B (zh) * | 2022-11-10 | 2024-04-16 | 重庆大学 | 前药封装的工程化益生菌及其制备方法与应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807824A (en) * | 1993-12-06 | 1998-09-15 | Ciba-Geigy Corporation | C5A receptor antagonists having substantially no agonist activity |
WO1995023865A1 (en) * | 1994-03-03 | 1995-09-08 | Genentech, Inc. | Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders |
US5614370A (en) * | 1994-03-18 | 1997-03-25 | Merck & Co., Inc. | Assay to identify human C5a antagonists and agonists |
EP0832223A1 (en) * | 1995-06-05 | 1998-04-01 | Novartis AG | C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY AND METHODS FOR PREPARATION |
SE9701219D0 (sv) * | 1997-04-04 | 1997-04-04 | Astra Pharma Prod | New compounds |
AUPO755097A0 (en) * | 1997-06-25 | 1997-07-17 | University Of Queensland, The | Receptor agonist and antagonist |
US6611377B1 (en) * | 2000-07-10 | 2003-08-26 | Intel Corporation | Micromechanical diffraction phase grating |
AUPR833401A0 (en) * | 2001-10-17 | 2001-11-08 | University Of Queensland, The | G protein-coupled receptor antagonists |
AUPS160602A0 (en) * | 2002-04-08 | 2002-05-16 | University Of Queensland, The | Therapeutic method |
AU2002952086A0 (en) * | 2002-10-16 | 2002-11-07 | The University Of Queensland | Treatment of osteoarthritis |
WO2004035078A1 (en) * | 2002-10-16 | 2004-04-29 | The University Of Queensland | Treatment of inflammatory bowel disease |
AU2003902586A0 (en) * | 2003-05-26 | 2003-06-12 | The University Of Queensland | Treatment of burns |
US7910945B2 (en) * | 2006-06-30 | 2011-03-22 | Cree, Inc. | Nickel tin bonding system with barrier layer for semiconductor wafers and devices |
-
2003
- 2003-10-15 WO PCT/AU2003/001365 patent/WO2004035078A1/en active Application Filing
- 2003-10-15 AT AT03750165T patent/ATE509632T1/de not_active IP Right Cessation
- 2003-10-15 US US10/531,564 patent/US7410945B2/en not_active Expired - Fee Related
- 2003-10-15 CA CA2542507A patent/CA2542507C/en not_active Expired - Fee Related
- 2003-10-15 JP JP2005501247A patent/JP4818726B2/ja not_active Expired - Fee Related
- 2003-10-15 EP EP03750165A patent/EP1558277B1/en not_active Expired - Lifetime
-
2008
- 2008-06-23 US US12/144,266 patent/US20090004264A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090004264A1 (en) | 2009-01-01 |
US7410945B2 (en) | 2008-08-12 |
JP4818726B2 (ja) | 2011-11-16 |
WO2004035078A1 (en) | 2004-04-29 |
US20060135411A1 (en) | 2006-06-22 |
JP2006505621A (ja) | 2006-02-16 |
EP1558277A1 (en) | 2005-08-03 |
EP1558277A4 (en) | 2009-07-29 |
ATE509632T1 (de) | 2011-06-15 |
CA2542507A1 (en) | 2004-04-29 |
EP1558277B1 (en) | 2011-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090004264A1 (en) | Methods for treating and ameliorating the symptons of inflammatory bowel diseases | |
US6399568B1 (en) | Cyclic tetrapeptide derivatives and medicinal use thereof | |
US20030114514A1 (en) | Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses | |
US7579432B2 (en) | Cyclic peptides as G-protein-coupled receptor antagonists | |
WO1992004370A1 (en) | Modified di- and tripeptidyl immunosuppressive compounds | |
RU2627065C2 (ru) | Пролекарственные композиции с высокой степенью проникновения на основе пептидов и родственных пептидам соединений | |
US20100267639A1 (en) | Treatment of osteoarthritis | |
WO2001056994A1 (en) | Integrin antagonists | |
KR20070036033A (ko) | 보체 C5a 수용체 조절제를 이용한 신경계 증상의치료방법 | |
IL298964A (en) | Manufacture, formulation and dosage of APRAGLUTIDE | |
NZ292287A (en) | Delta opiod receptor antagonist and mu opiod receptor agonist | |
JP2006528208A (ja) | コンプリメント5a受容体阻害剤を使用する出血ショックの処置 | |
AU2003269602B2 (en) | Treatment of inflammatory bowel disease | |
AU2003269602A1 (en) | Treatment of inflammatory bowel disease | |
US20070021329A1 (en) | Treatment of hypersensitivity conditions | |
ES2366538T3 (es) | Tratamiento de la enfermedad inflamatoria intestinal. | |
AU2003266862B2 (en) | Treatment of hypersensitivity conditions | |
US20070054841A1 (en) | Method of treatment of systemic injury secondary to burns | |
AU2003266862A1 (en) | Treatment of hypersensitivity conditions | |
AU2004238089A1 (en) | Treatment of haemorrhagic shock using complement 5a receptor inhibitors | |
MXPA00006270A (en) | Kappa receptor opioid peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20141015 |